Welcome to our dedicated page for Psybio Therapeau news (Ticker: PSYBF), a resource for investors and traders seeking the latest updates and insights on Psybio Therapeau stock.
PsyBio Therapeutics Corp (PSYBF) is advancing innovative mental health treatments through its proprietary bio-medicinal chemistry platform. This news hub provides investors and researchers with official updates on clinical developments, regulatory milestones, and scientific breakthroughs.
Access verified information about PsyBio's biosynthetic tryptamine research, including their lead compound PsyBio-11142 currently progressing toward human trials. The curated news collection covers essential updates including:
• Government regulatory approvals
• Clinical trial phase advancements
• Intellectual property developments
• Research methodology innovations
• Strategic industry partnerships
Bookmark this page for direct access to PsyBio's official communications, ensuring you stay informed about their pioneering work in psycho-targeted therapeutics. Check regularly for updates on their novel approach to neurological health solutions derived from naturally occurring compounds.
PsyBio Therapeutics Corp. (TSXV: PSYB, OTCQB: PSYBF) will be presenting at the KCSA Psychedelics Investor Conference on October 14th at 10:30 a.m. ET. The conference aims to showcase innovative biotechnology focused on developing psycho-targeted therapeutics for mental health improvement. Interested participants can register here. PsyBio's expertise lies in drug discovery through synthetic biology and metabolic engineering, utilizing psychoactive compounds derived from hallucinogenic mushrooms to develop novel therapies.
PsyBio Therapeutics Corp. (OTCQB: PSYBF) announced the commencement of trading of its subordinate voting shares on the OTCQB Venture Market on July 14, 2021. This listing aims to increase visibility among U.S. investors and enhance liquidity for shareholders. The company is also applying for DTC eligibility, which will facilitate electronic settlement of stock transfers, making it easier for investors. PsyBio continues to trade on the TSX Venture Exchange as PSYB and on the Frankfurt Stock Exchange as PSYB.F.
FAQ
What is the current stock price of Psybio Therapeau (PSYBF)?
What is the market cap of Psybio Therapeau (PSYBF)?
